ADX-71149

ADX-71149
Clinical data
ATC code None
Identifiers
CAS Number 1127498-03-6
PubChem (CID) 25195461
IUPHAR/BPS 8946
ChemSpider 28424210
UNII 612BYT76F3 YesY
ChEMBL CHEMBL3337527
Chemical and physical data
Formula C20H25ClN2O
Molar mass 344.88 g·mol−1
3D model (Jmol) Interactive image

ADX-71149, also known as JNJ-40411813 and JNJ-mGluR2-PAM, is a selective positive allosteric modulator of the mGlu2 receptor.[1][2][3] It is being studied by Addex Therapeutics and Janssen Pharmaceuticals for the treatment of schizophrenia.[4] It was also researched by these companies for the treatment of anxious depression (major depressive disorder with anxiety symptoms),[5] but although some efficacy was observed in clinical trials, it was not enough to warrant further development for this indication.[6] As of 2015, ADX-71149 is in phase II clinical trials for schizophrenia.[4]

See also

References

  1. ↑ Cid, José María; Tresadern, Gary; Duvey, Guillaume; Lütjens, Robert; Finn, Terry; Rocher, Jean-Philippe; Poli, Sonia; Vega, Juan Antonio; de Lucas, Ana Isabel; Matesanz, Encarnación; Linares, María Lourdes; Andrés, José Ignacio; Alcazar, Jesús; Alonso, José Manuel; Macdonald, Gregor J.; Oehlrich, Daniel; Lavreysen, Hilde; Ahnaou, Abdelah; Drinkenburg, Wilhelmus; Mackie, Claire; Pype, Stefan; Gallacher, David; Trabanco, Andrés A. (2014). "Discovery of 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): A Novel Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor". Journal of Medicinal Chemistry. 57 (15): 6495–512. doi:10.1021/jm500496m. PMID 25032784.
  2. ↑ Lavreysen, Hilde; Ahnaou, Abdellah; Drinkenburg, Wilhelmus; Langlois, Xavier; Mackie, Claire; Pype, Stefan; Lütjens, Robert; Le Poul, Emmanuel; Trabanco, Andrés A.; Nuñez, José María Cid (2015). "Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor". Pharmacology Research & Perspectives. 3 (1): e00096. doi:10.1002/prp2.96. PMC 4317228Freely accessible. PMID 25692015.
  3. ↑ Lavreysen, Hilde; Langlois, Xavier; Donck, Luc Ver; Nuñez, José María Cid; Pype, Stefan; Lütjens, Robert; Megens, Anton (2015). "Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813". Pharmacology Research & Perspectives. 3 (2): e00097. doi:10.1002/prp2.97. PMC 4324682Freely accessible. PMID 25692027.
  4. 1 2 Walker, Adam G; Conn, P Jeffrey (2015). "Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics". Current Opinion in Pharmacology. 20: 40–5. doi:10.1016/j.coph.2014.11.003. PMC 4318747Freely accessible. PMID 25462291.
  5. ↑ Dunlop, John; Brandon, Nicholas J (2015). "Schizophrenia drug discovery and development in an evolving era: Are new drug targets fulfilling expectations?". Journal of Psychopharmacology. 29 (2): 230–8. doi:10.1177/0269881114565806. PMID 25586401.
  6. ↑ Addex Therapeutics (7 February 2014). "Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms". Retrieved 24 May 2015.

External links


This article is issued from Wikipedia - version of the 8/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.